Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys
References (51)
- et al.
Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey
Brain Res. Bull.
(1986) - et al.
Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys
Neuroscience
(1986) - et al.
Symptomatic and asymptomic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-related primates: Biochemical changes in striatal regions
Neuroscience
(1989) - et al.
Dihydrexidine, a novel selective high potency full D1 receptor agonist
Eur. J. Pharmacol.
(1989) - et al.
II. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys
Brain Res.
(1990) - et al.
Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys
Brain Res.
(1993) - et al.
Deficits in behavioral initiation and execution processes inn monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism
Neurosci. Lett.
(1985) - et al.
Dopamine receptors labelled by [3H] quinpirole
Eur. J. Pharmacol.
(1991) Distractability in early Parkinson's disease
Cortex
(1990)- et al.
CSF monoamine metabolites in children with minimal brain dysfunction: Evidence for alteration of brain dopamine
J. Pediatr.
(1977)
Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys
Eur. J. Pharmacol.
Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years?
J. Am. Acad. Child Adolesc. Psychiatry
The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes
J. Neurosci.
Behavioral and receptor binding analysis of the alpha-2 adrenergic agonist, 5-bromo-6[2-imidazoline-2-yl amino] quinoxaline (UK-14304): Evidence for cognitive enhancement at an alpha-2 adrenoceptor subtype
Neuropharmacology
Attention deficit disorder with and without hyperactivity: Clinical response to three dose levels of methylphenidate
Pediatrics
Comparison of the effects of frontal and caudate lesions on delayed response and alternation in monkeys
J. Comp. Psychol.
Levodopa-induced dyskinesia: Facts and fancy. What does the MPTP monkey model tell us?
Can. J. Neurol. Sci.
Differential effects of D1 and D2 agonists in MPTP-treated primates: Functional implications for Parkinson's disease
Neurology
Selective D1 dopamine receptor agonist treatment of Parkinson's disease
J. Neural. Transm.
A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Sensorimotor disinhibition in Parkinson disease: Effects of levodopa
Ann. Neurol.
Effects of methylphenidate on hyperactive children's ability to sustain attention
Pediatrics
Failure of SKF-38393-A to relieve parkinsonian symptoms induced by MPTP in the marmoset
Br. J. Pharmacol.
receptor antagonism and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced hemiparkinsonian monkeys
J. Pharmacol. Exp. Ther.
Neuropsychiatric sequelae of acute epidemic encephalitisin children
Am. J. Dis. Child.
Cited by (44)
Methylphenidate does not enhance visual working memory but benefits motivation in macaque monkeys
2016, NeuropharmacologyCitation Excerpt :Rajala et al. (2012) reported a dose-dependent increase in the amount of time monkeys engaged in the task. Schneider et al. (1994) reported that DA-depleted (MPTP-treated) monkeys seemed more focused while performing a delayed response task after MPH treatment, which decreased the occurrence of omissions, without a significant effect on errors. Overall, MPH may exert its effects by enhancing task engagement.
Methods and Models of the Nonmotor Symptoms of Parkinson Disease
2015, Movement Disorders: Genetics and Models: Second EditionPersistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis
2009, Neuroscience and Biobehavioral ReviewsInteraction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model
2009, Brain ResearchCitation Excerpt :The animals also develop deficits in performing delayed response and delayed matching to sample tasks (Schneider and Kovelowski, 1990; Schneider and Roeltgen, 1993), although deficits on these tasks are more attentional-related than memory-related per se (Decamp et al., 2004). Although dopaminergic therapies have had little or no positive effect on performance of these tasks in these animals (Schneider et al., 1994, 1998), nicotine and nicotinic receptor subtype selective agonists have shown efficacy in ameliorating many of the cognitive deficits in chronic low dose MPTP-treated animals (Decamp and Schneider, 2006; Schneider et al., 1998, 1999, 2003b). However, since nicotinic therapies would be used clinically as adjuncts to levodopa administration it is important to know how these two therapies interact.
Reprint of "Neurobiology of animal models of attention-deficit hyperactivity disorder"
2007, Journal of Neuroscience Methods